Tempest Therapeutics, Inc. (TPST) — 10-Q Filings

10-Q Filings (6)

• Tempest's Cash Dwindles Amid Strategic Review, R&D Cuts — Nov 5, 2025 Risk: high
  Tempest Therapeutics, Inc. (TPST) reported a net loss of $3.51 million for the three months ended September 30, 2025, a significant improvement from the $10.56
• Tempest's Q2 Net Loss Widens to $20.5M Amid R&D Spend — Aug 11, 2025 Risk: high
  Tempest Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its clinical-stage status. The company's net lo
• Tempest Therapeutics Files Q1 2025 10-Q — May 13, 2025 Risk: medium
  Tempest Therapeutics, Inc. filed its Q1 2025 10-Q report on May 13, 2025, for the period ending March 31, 2025. The company, formerly known as OvaScience, Inc.
• Tempest Therapeutics Files Q3 2024 10-Q — Nov 12, 2024 Risk: medium
  Tempest Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial position and operations, including det
• Tempest Therapeutics Files Q2 2024 10-Q — Aug 8, 2024 Risk: medium
  Tempest Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business o
• Tempest Therapeutics Files 10-Q for Period Ending March 31, 2024 — May 9, 2024 Risk: low
  Tempest Therapeutics, Inc. (TPST) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Tempest Therapeutics, Inc. filed a 10-Q report for the period end

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX